suMMARY A rapid and simplified technique for detecting hepatitis B virus (HBV) DNA by spot hybridisation in the sera of patients with different clinical forms of HBV infection was investigated using enzyme conjugated synthetic oligodeoxyribonucleotides as probes. These are able to hybridise to the S and C regions of the HBV L(-) DNA strand. When compared with a complete 32P-labelled HBV DNA probe, the synthetic oligonucleotides provided a sensitive and quick method for the routine survey of HBV infection. Moreover, the DNA extraction procedure used allowed the spot hybridisation technique to be applied and read easily and the results obtained within a few hours.
Hepatitis B virus (HBV) infection is currently a
problem of worldwide relevance.' Its control at present largely depends on both laboratory diagnosis and evaluation ofinfectivity,2 and molecular hybridisation techniques have provided a sensitive and specific approach to the detection of HBV DNA sequences in serum samples and tissues. 3 Moreover, when a large number of samples needs to be tested for routine purposes, these methods represent a quick and useful tool for the widespread survey of the infection.s' The availability of radiolabelled DNA probes for routine diagnosis, however, is limited to a few laboratories because of the need for propagating, isolating, purifying and labelling procedures. Moreover, as autoradiography requires from 48 hours to two weeks for the results to be read, the use of such probes does not allow a rapid diagnosis to be made. On the other hand, production of biotinylated7 HBV DNA probes has only partially overcome this problem. In fact, hybridisation by cloned, complete biotinylated probes, detected by complexing with streptavidin conjugated to an enzyme, has been shown to be relatively insensitive in some circumstances,8 compared with the 32P-labelled probes or different cold probes.
As the importance of and the interest in using sensitive non-radioactive HBV DNA probes for routine purposes has been underlined recently9 and the Accepted for publication 25 May 1989 complete sequence of several cloned HBV serotypes is known,'°01 a potential approach lies in the use of synthetic, enzyme conjugated oligodeoxyribonucleotides as probes which can hybridise to specific sites on the HBV L(-) strand.
To investigate this possibility, synthetic oligodeoxyribonucleotides, which are specifically recognised by fragments ofthe S and C open reading frames ofthe HBV genome, were used to test serum samples from different groups of patients infected with HBV.
Material and methods
Serum samples from 213 HBsAg chronic carriers and 25 patients with acute hepatitis B were tested for the presence of HBV DNA sequences. Serological markers ofHBV infection (HBsAg, anti-HBs, HBeAg, anti-HBe, total anti-HBc and IgM anti-HBc) were detected using a commercially available enzyme immunoassay (EIA) (Connaught Laboratories, Ontario, Canada). Laboratory diagnosis of acute hepatitis B was performed using the methods mentioned above, excluding hepatitis A virus, cytomegalovirus, and Epstein-Barr virus infections, which were assayed using routine EIA methods for specific IgM antibodies.
SYNTHETIC OLIGONUCLEOTIDE PROBES
Sequence data for ayw,'0 adw, and adr subtypes" were studied comparatively, and oligonucleotide sequences Use ofsynthetic non-radioactive oligonucleotides to detect HBV in the S and C regions of HBV DNA were chosen to avoid mismatches greater than 20%. The oligonucleotide sequences for the S and C regions of the HBV genome were synthesised and purified using reverse phase high pressure liquid chromatography by Molecular Biosystems (San Diego, California, USA), consisting, respectively, of synthetic 26 and 25 bases complementary to nucleotides from 209 to 234, and from nucleotides 1983 to 2007 of the ayw L(-) strand.'"
The probes were covalently linked to alkaline phosphatase at the C-5 position of a thymidine through a 12-atom spacer arm and lyophilised. Finally, the lyophilised probes were resuspended in deionised, sterilised water which resulted in a 10 pg/100 p1 stock of each probe.
32P-LABELLED PROBE
The probe used was the purified HBV DNA (subtype ayw) inserted in tandem into the EcoRI restriction site of a pBR322 plasmid'°and labelled with 32P d-TTP by the nick translation method'2; the specific activity was [4] [5] [6] For the hybridisation assay using the cold, synthetic probes, redissolved DNA (50 p1) was applied to nylon filters (Bio-Rad, Richmond, California, USA) using vacuum filtration apparatus (Bio-Dot Apparatus, Bio-Rad, Richmond, California, USA), and then denatured in situ in 0-5 M NaOH, 15 M NaCl for 10 minutes, neutralised in 1-5 M NaCl, 0-5 Tris-HCl (pH 8 0) for 10 minutes, and then dried for one hour in a vacuum oven at 80°C.
The filters were pre-hybridised for 15 minutes in pre-warmed hybridisation buffer at 50°C. The hybridisation solution was 5x SSC (lx SSC is 0-15 M NaCI, 0-015 M sodium citrate), 0-5% bovine serum albumin (BSA), 0 5% polyvinylpirrolidone (PVP) and 1% SDS. The hybridisation was performed at 50°C for 30 minutes in the same buffer containing 5 pl/ml of the stock of probes. The filters were washed twice with 50 ml of lx SSC, 1% SDS at room temperature, followed by two washes with lx SSC, 1% Triton X-100 at the hybridisation temperature, and finally two washes with lx SSC at room temperature.
Hybridisation with the purified, 32P-labelled complete probe was carried out according to Weller et al3 with minor modifications. The filters were hybridised at 42°C for 50-60 hours in 50 ml of a solution containing 50% formamide, 5x SSC, lx Denhardt's solution (Ficoll 400, PVP 360, BSA 0-2 mg/ml each), 0-02 M NaPi (pH 7T0), 0 05% SDS, 50
Mg/ml denatured salmon sperm DNA, and 108 dpm of 32P-labelled nick-translated HBV DNA probe.
The unincorporated radioactivity was removed by washing out with the following solutions: (i) 5x SSC, 0-1% SDS, 50% formamide at 42°C for 30 minutes;
(ii) 2x SSC, 0-1% SDS at 65°C for 30 minutes.
HYBRIDISATION DETECTION
Alkaline phosphatase was detected in 7-5 ml of a substrate buffer (100 mM TRIS-HCI pH 8 (table 1) . Serum HBV DNA was not found in HBeAg/ anti-HBe negative carriers, nor in different groups of subjects negative for serological HBV markers, nor in subjects with anti-HBc or anti-HBs antibodies, or a combination. HBV DNA negative samples were not strongly positive when tested using the 32P-labelled HBV DNA, but two HBeAg and one anti-HBe positive/HBsAg carrier, negative using oligonucleotides, were borderline positive for HBV DNA after one week's exposure to the radioactive probe (table 1) .
Furthermore, a sensitivity test was performed using a plasmid control DNA (100 ng/ml) containing 10I genomic copies/ng, thus finding a 10-fold and a 20-fold loss of sensitivity when comparing, respectively, the S and C probes with the complete, 32P-labelled probe (data not shown). In this study we investigated the use of non-radioactive oligodeoxyribonucleotides for detecting HBV DNA in the sera of patients with acute or persistent HBV infection. In our opinion, several general aspects may particularly lead to the use of synthetic oligonucleotides as probes; firstly, recent reports clearly discuss the possibility of spurious hybridisation when Table 2 A third aspect concerns the sensitivity of the test. Generally, molecular hybridisation methods have exhibited high levels of sensitivity in detecting specific DNA sequences when 32P-labelled probes are used. Sensitivity of non-radioactive methods is generally lower and problems of interpreting results may be present when borderline samples are tested. Additionally, spotting serum samples on to nylon or nitrocellulose filters directly may make a radioactive method easier,4 but it may also interfere with the reading of low levels of enzymatic reaction. These are the main reasons why we adopted the DNA extraction procedure reported above, which allows results to be read more easily.
A method of amplifying short DNA fragments that enhances the sensitivity of hybridisation procedures has recently been described,2' and preliminary results on HBV DNA detection using a short (128 nucleotides), 32P-labelled DNA fragment complementary to part of the S gene have been satisfactory.' Clearly, the application of this assay to HBV DNA detection using a non-radioactive method could be of great interest.
Our results indicate that, although a low concentration of HBV DNA has been detected using the complete 32P-labelled probe in three samples giving negative results when using the oligonucleotide probes, the sensitivity of the two cold probes used was acceptable for diagnostic purposes. The results obtained in terms of prevalence of HBV DNA positive/HBsAg carriers by using the synthetic probes are in line with previous data obtained using a complete 32P-labelled probe. '6 Furthermore, because one of the main purposes of HBV DNA detection in human sera is to have a handy tool to test sequential samples from treated chronic carriers, we examined the sera of patients treated with a-interferon. The loss of positivity using the oligonucleotide probe for the C region of the HBV genome was faster during treatment than for the S probe. This probably reflects the lower detection rate observed with the second oligonucleotide, and the different sensitivities of the two probes probably reflect the higher sequence variation in the region homologous to the C probe, compared with the region homologous to the S probe, among different subtypes. It was also predictive of the decrease in HBV DNA and, in three cases, of HBe/anti-HBe seroconversion, and of the complete clearance of HBV replication.
In conclusion, the results point to the usefulness of synthetic oligodeoxyribonucleotides as cold probes for the detection of HBV DNA in sera by spot hybridisation, thus highlighting this technology as an important tool in the survey of HBV infection in clinical laboratories. In our opinion, this alternative approach using non-radioactive probes is clearly of value, and further development and improvement may well generate diagnostic assays for general use. One possible approach would be to use several oligonucleotides from regions of the genome which show little sequence variation between viral subtypes, because if appropriately chosen, there would be no steric hindrance and a stronger signal.
